TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Knee Arthroscopy Cohort Southern Denmark (KACS)
Brief Summary: PURPOSE: To investigate the natural time course of patient-reported outcomes after meniscus surgery and identify factors associated with good and bad outcome after surgery.


Options:
A: Arm Label: Arthroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic meniscal repair or resection | Arm Label: Exercise and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and education | Intervention Type: PROCEDURE; Name: Arthroscopic meniscal repair or resection; Assigned to Arm(s): Arthroscopy | Intervention Type: BEHAVIORAL; Name: Exercise and education; Assigned to Arm(s): Exercise and Education
B: Arm Label: Meniscus Injury Patients; Type: N/A; Interventions: Procedure: Arthroscopic Meniscus Surgery | Intervention Type: PROCEDURE; Name: Arthroscopic Meniscus Surgery; Assigned to Arm(s): Meniscus Injury Patients
C: Arm Label: Arthroscopic partial meniscectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic partial meniscectomy | Arm Label: Arthroscopy (diagnostic); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopy (diagnostic) | Intervention Type: PROCEDURE; Name: Arthroscopic partial meniscectomy; Assigned to Arm(s): Arthroscopic partial meniscectomy | Intervention Type: PROCEDURE; Name: Arthroscopy (diagnostic); Assigned to Arm(s): Arthroscopy (diagnostic)
D: Arm Label: Surgical; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy, Other: Postoperative rehabilitative physical therapy | Arm Label: Nonoperative; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard physical therapy | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Surgical | Intervention Type: OTHER; Name: Standard physical therapy; Assigned to Arm(s): Nonoperative | Intervention Type: OTHER; Name: Postoperative rehabilitative physical therapy; Assigned to Arm(s): Surgical

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 7% Hypertonic Saline for Acute Bronchiolitis: A Randomized Controlled Trial
Brief Summary: Research suggests that hypertonic saline may improve mucous flow in infants with acute bronchiolitis. Data suggest a trend favoring reduced length of hospital stay and improved pulmonary scores with increasing concentration of nebulized solution to 3% and 5% saline as compared to 0.9% saline mixed with epinephrine. To our knowledge, 7% hypertonic saline has not been previously investigated. OUr hypothesis was that 7% hypertonic saline would improve bronchiolitis severity scores and admission rate.


Options:
A: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
B: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 0.9% saline | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 3% hypertonic saline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 0.9% saline; Assigned to Arm(s): 2
D: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% saline; Assigned to Arm(s): Nebulized 0.9% Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 7% Hypertonic Saline for Acute Bronchiolitis: A Randomized Controlled Trial
Brief Summary: Research suggests that hypertonic saline may improve mucous flow in infants with acute bronchiolitis. Data suggest a trend favoring reduced length of hospital stay and improved pulmonary scores with increasing concentration of nebulized solution to 3% and 5% saline as compared to 0.9% saline mixed with epinephrine. To our knowledge, 7% hypertonic saline has not been previously investigated. OUr hypothesis was that 7% hypertonic saline would improve bronchiolitis severity scores and admission rate.


Options:
A: Arm Label: 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% Saline | Arm Label: 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline | Intervention Type: DRUG; Name: 3% Saline; Assigned to Arm(s): 3% Saline | Intervention Type: DRUG; Name: 0.9% Normal Saline; Assigned to Arm(s): 0.9% Normal Saline
B: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% saline; Assigned to Arm(s): Nebulized 0.9% Saline
C: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
D: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia
Brief Summary: The overall aim of this study is two fold:

1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia.
2. to understand the micro-epidemiology of malaria in these areas; chiefly, the prevalence and importance to on-going transmission of sub-clinical p.f malaria infections.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
B: Arm Label: MDA with DHAp (Eurartesim); Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp (Eurartesim) | Arm Label: Focal MDA with DHAp (Eurartesim); Type: EXPERIMENTAL; Interventions: Drug: Focal MDA with DHAp (Eurartesim) | Arm Label: Standard of Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp (Eurartesim); Assigned to Arm(s): MDA with DHAp (Eurartesim) | Intervention Type: DRUG; Name: Focal MDA with DHAp (Eurartesim); Assigned to Arm(s): Focal MDA with DHAp (Eurartesim)
C: Arm Label: MDA with DHAp and SLD Primaquine; Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp and SLD Primaquine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp and SLD Primaquine; Assigned to Arm(s): MDA with DHAp and SLD Primaquine
D: Arm Label: malaria elimination using DP and low-dose primaquine; Type: EXPERIMENTAL; Interventions: Drug: malaria elimination using DP and low-dose primaquine | Arm Label: Control villages; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: malaria elimination using DP and low-dose primaquine; Assigned to Arm(s): malaria elimination using DP and low-dose primaquine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sedation Versus General Anesthesia for Endovascular Therapy in Acute Stroke - Impact on Neurological Outcome
Brief Summary: The purpose of this study is to evaluate whether general anesthesia or sedation technique is preferable during embolectomy for stroke, measured in terms of three months neurological impairment. In addition we study if there is any difference between the methods regarding complication frequency.


Options:
A: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
B: Arm Label: GA with mild hypercarbia (GAH); Type: ACTIVE_COMPARATOR; Interventions: Other: Tight control of end-tidal CO2 levels | Arm Label: GA with normocarbia (GAN); Type: ACTIVE_COMPARATOR; Interventions: Other: Tight control of end-tidal CO2 levels | Intervention Type: OTHER; Name: Tight control of end-tidal CO2 levels; Assigned to Arm(s): GA with mild hypercarbia (GAH), GA with normocarbia (GAN)
C: Arm Label: General Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Local Anesthesia; Type: EXPERIMENTAL; Interventions: Procedure: Local anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia; Assigned to Arm(s): Local Anesthesia
D: Arm Label: General anaesthesia; Type: EXPERIMENTAL; Interventions: Drug: Sevorane Remifentanil | Arm Label: Sedation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Remifentanil | Intervention Type: DRUG; Name: Sevorane Remifentanil; Assigned to Arm(s): General anaesthesia | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): Sedation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial
Brief Summary: The purpose of this study is to demonstrate that heated, humidified, high-flow nasal cannula (HHHFNC) is superior to hypertonic saline solution (HSS) in the treatment of moderate acute viral bronchiolitis in infants in improving respiratory distress and comfort and reducing length of hospital stay (LOS) and admission to Pediatric Intensive Care Unit (PICU).


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
B: Arm Label: HSS (3%) + epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epinephrine 1/1000, Drug: HSS 3% | Arm Label: HHHFNC+epinephrine+Normal Saline(0.9%); Type: EXPERIMENTAL; Interventions: Drug: Epinephrine 1/1000, Device: HHHFNC, Drug: NS (0.9%) | Intervention Type: DRUG; Name: Epinephrine 1/1000; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%), HSS (3%) + epinephrine | Intervention Type: DRUG; Name: HSS 3%; Assigned to Arm(s): HSS (3%) + epinephrine | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%) | Intervention Type: DRUG; Name: NS (0.9%); Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%)
C: Arm Label: NaCl 3% inhalations + standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: NaCl 3%, Other: Standard therapy | Arm Label: Standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard therapy | Intervention Type: DRUG; Name: NaCl 3%; Assigned to Arm(s): NaCl 3% inhalations + standard therapy | Intervention Type: OTHER; Name: Standard therapy; Assigned to Arm(s): NaCl 3% inhalations + standard therapy, Standard therapy
D: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial
Brief Summary: The purpose of this study is to demonstrate that heated, humidified, high-flow nasal cannula (HHHFNC) is superior to hypertonic saline solution (HSS) in the treatment of moderate acute viral bronchiolitis in infants in improving respiratory distress and comfort and reducing length of hospital stay (LOS) and admission to Pediatric Intensive Care Unit (PICU).


Options:
A: Arm Label: bubble CPAP; Type: EXPERIMENTAL; Interventions: Procedure: Bubble continuous positive airway pressure | Arm Label: High flow air/ oxygen mix; Type: EXPERIMENTAL; Interventions: Procedure: Humidified high flow air / O2 mix at 2 l/kg/min | Arm Label: Standard O2 supplementation by nasal prongs; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min | Intervention Type: PROCEDURE; Name: Bubble continuous positive airway pressure; Assigned to Arm(s): bubble CPAP | Intervention Type: PROCEDURE; Name: Humidified high flow air / O2 mix at 2 l/kg/min; Assigned to Arm(s): High flow air/ oxygen mix | Intervention Type: PROCEDURE; Name: Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min; Assigned to Arm(s): Standard O2 supplementation by nasal prongs
B: Arm Label: HSS (3%) + epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epinephrine 1/1000, Drug: HSS 3% | Arm Label: HHHFNC+epinephrine+Normal Saline(0.9%); Type: EXPERIMENTAL; Interventions: Drug: Epinephrine 1/1000, Device: HHHFNC, Drug: NS (0.9%) | Intervention Type: DRUG; Name: Epinephrine 1/1000; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%), HSS (3%) + epinephrine | Intervention Type: DRUG; Name: HSS 3%; Assigned to Arm(s): HSS (3%) + epinephrine | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%) | Intervention Type: DRUG; Name: NS (0.9%); Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%)
C: Arm Label: high flow nasal cannula (HFNC); Type: ACTIVE_COMPARATOR; Interventions: Device: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices | Arm Label: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV); Type: ACTIVE_COMPARATOR; Interventions: Device: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices | Intervention Type: DEVICE; Name: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices; Assigned to Arm(s): high flow nasal cannula (HFNC), nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)
D: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial
Brief Summary: The purpose of this study is to demonstrate that heated, humidified, high-flow nasal cannula (HHHFNC) is superior to hypertonic saline solution (HSS) in the treatment of moderate acute viral bronchiolitis in infants in improving respiratory distress and comfort and reducing length of hospital stay (LOS) and admission to Pediatric Intensive Care Unit (PICU).


Options:
A: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)
B: Arm Label: HSS (3%) + epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epinephrine 1/1000, Drug: HSS 3% | Arm Label: HHHFNC+epinephrine+Normal Saline(0.9%); Type: EXPERIMENTAL; Interventions: Drug: Epinephrine 1/1000, Device: HHHFNC, Drug: NS (0.9%) | Intervention Type: DRUG; Name: Epinephrine 1/1000; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%), HSS (3%) + epinephrine | Intervention Type: DRUG; Name: HSS 3%; Assigned to Arm(s): HSS (3%) + epinephrine | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%) | Intervention Type: DRUG; Name: NS (0.9%); Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%)
C: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline
D: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective?
Brief Summary: The hypothesis is that there is a profit potential by implementing a multifactorial nutritional intervention among frail elderly since this will result in an improved nutritional status, functional capacity and improved quality of life.


Options:
A: Arm Label: New Flooring; Type: EXPERIMENTAL; Interventions: Other: New flooring | Arm Label: Standard Flooring; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New flooring; Assigned to Arm(s): New Flooring
B: Arm Label: Multifactorial nutritional intervention; Type: EXPERIMENTAL; Interventions: Other: multifactorial nutritional intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: multifactorial nutritional intervention; Assigned to Arm(s): Multifactorial nutritional intervention
C: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care
D: Arm Label: Mulitfaceted podiatry Intervention; Type: EXPERIMENTAL; Interventions: Other: Foot and ankle exercises, foot orthoses, footwear provision | Arm Label: Usual podiatry care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Foot and ankle exercises, foot orthoses, footwear provision; Assigned to Arm(s): Mulitfaceted podiatry Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual podiatry care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared to GA 20 mg/mL every day (QD) administered SC.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: GA 20 mg/mL every day; Type: ACTIVE_COMPARATOR; Interventions: Drug: GA 20 mg/mL | Arm Label: GA 40 mg/mL 3 times a week; Type: EXPERIMENTAL; Interventions: Drug: GA 40 mg/mL | Intervention Type: DRUG; Name: GA 20 mg/mL; Assigned to Arm(s): GA 20 mg/mL every day | Intervention Type: DRUG; Name: GA 40 mg/mL; Assigned to Arm(s): GA 40 mg/mL 3 times a week
C: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
D: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A

Answer: B